

## List of Tables, Figures, and Boxes

### TABLES

- ES-1** UNOS Liver Status for Patients  $\geq 18$  Years of Age According to Disease Severity
- ES-2** Summary of Literature on Cold Ischemic Times for Solid Organs
- 1-1** Number of Organ Transplants Performed in 1998
- 1-2** UNOS National Patient Waiting List by Organ (as of May 12, 1999)
- 1-3** Number of Registrations on the National Transplant Waiting List by Organ at Year End 1988–1998
- 2-1** UNOS Liver Status for Patients  $\geq 18$  Years of Age According to Disease Severity
- 4-1** Number of Cadaveric Donors by Age from 1994 through October 31, 1998
- 4-2** Number of Cadaveric Donors by Race from 1994 through October 31, 1998
- 5-1** Characteristics of Liver Transplant Patients by Status, 1995-1999
- 5-2** Parameter Estimates (Standard Errors) for Likelihood of Liver Transplantation as a Function of Time, Age, Gender, Race, and OPO Volume. Individual Models for Statuses 1, 2B, and 3 for All Available Data in 1998-1999.
- 5-3** Parameter Estimates (Standard Errors) for Likelihood of Pretransplant Mortality as a Function of Time, Age, Gender, Race, and OPO Volume. Individual Models for Statuses 1, 2B, and 3 for All Available Data in 1998-1999.

- 5-4** Parameter Estimates (Standard Errors) for Likelihood of Liver Transplantation as a Function of Time, and Linear and Nonlinear Effects of OPO Size (in millions). Individual Models for Statuses 1, 2B, and 3 for All Available Data in 1998-1999.
- 5-5** Parameter Estimates (Standard Errors) for Likelihood of Pretransplantation Mortality as a Function of Time, and Linear and Nonlinear Effects of OPO Size (in millions). Individual Models for Statuses 1, 2B, and 3 for All Available Data in 1998-1999.
- 6-1** Summary of Literature on Cold Ischemic Times for Solid Organs
- 6-2** Heart: Summary of Literature on Cold Ischemic Time
- 6-3** Kidney: Summary of Literature on Cold Ischemic Time
- 6-4** Liver: Summary of Literature on Cold Ischemic Time
- 6-5** Lung: Summary of Literature on Cold Ischemic Time
- 6-6** Pancreas: Summary of Literature on Cold Ischemic Time
- 7-1** Economic Concepts in Health Care
- 7-2** Estimated Billed Charges (\$1,000s) for Organ Transplants, 1996
- 7-3** Average Billed Charges (in 1996 Dollars) per Transplant in the First Year Following Transplantation
- 7-4** Information on Medicare-Covered Liver Transplant Recipients, Calendar Year 1995 through 1998
- B-1** Transplants, Mortality, Waiting Time, and Demographics by OPO Patients During Status 1, Sorted by OPO Volume, 1995–1999
- B-2** Transplants, Mortality, Waiting Time, and Demographics by OPO Patients During Status 1, Sorted by OPO Volume-Adults Only (18 and over), 1995–1999
- B-3** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 1: Maximum Marginal Likelihood Estimates (MMLE), 1998–1999
- B-4** Transplants, Mortality, Waiting Time, and Demographics by OPO Patients During Status 2, Sorted by OPO Volume, 1995–1999
- B-5** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 2B: Maximum Marginal Likelihood Estimates (MMLE), 1998–1999
- B-6** Transplants, Mortality, Waiting Time, and Demographics by OPO Patients During Status 3 or 4, Sorted by OPO Volume, 1995–1999
- B-7** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 3: Maximum Marginal Likelihood Estimates (MMLE), 1998–1999
- B-8** Status of Transplanted Patients by OPO, Percentages (1995–1999)
- B-9** Initial Listing Status by OPO, Percentages (1995–1999)

- B-10** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 1 as a Function of OPO Size: Maximum Marginal Likelihood Estimates (MMLE)
- B-11** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 2B as a Function of OPO Size: Maximum Marginal Likelihood Estimates (MMLE)
- B-12** Mixed-Effects Competing Risk Survival Model for Patient Time in Status 3 as a Function of OPO Size: Maximum Marginal Likelihood Estimates (MMLE)
- B-13** Ratios of Transplants to Listings by OPO Sorted by Number of Transplants; Ratios Expressed as a Percentage
- B-14** Number of Transplants (overall and by status) and Number of Listings per Million People Served Sorted by Number of Transplants
- C-1** Child-Turcotte-Pugh (CTP) Scoring Systems to Assess Severity of Liver Disease
- C-2** American Liver Tumor Study Group Modified Tumor-Node-Metastasis (TNM) Staging Classifications (1)

### FIGURES

- ES-1** a. Monthly Liver Transplantation Rates, Status 2B Patients (by probability of transplant and OPO size)  
b. Monthly Mortality Rates, Status 2B Liver Patients (by probability of death and OPO size)
- ES-2** a. Monthly Liver Transplantation Rates, Status 3 Patients (by probability of transplant and OPO size)  
b. Monthly Mortality Rates, Status 3 Liver Patients (by probability of death and OPO size)
- 1-1** Geographic Boundaries Currently Used to Allocate Organs
- 5-1** Maps of Median Waiting Times in Status  
Panel 1: All Patients  
Panel 2: Patients Ever in Status 1  
Panel 3: Patients Ever in Status 2A  
Panel 4: Patients Ever in Status 2B  
Panel 5: Patients Ever in Status 3
- 5-2** a. Estimated Daily Hazard Rates, Status 1  
b. Cumulative Time-to-Event Distributions, Status 1
- 5-3** a. Estimated Monthly Hazard Rates, Status 2B  
b. Cumulative Time-to-Event Distributions, Status 2B
- 5-4** a. Estimated Monthly Hazard Rates, Status 3  
b. Cumulative Time-to-Event Distributions, Status 3

- 5-5** a. Daily Liver Transplantation Rates, Status 1 Patients (by Probability of Transplant and OPO size)
- b. Daily Mortality Rates, Status 1 Liver Patients (by probability of death and OPO size)
- 5-6** a. Monthly Liver Transplantation Rates, Status 2B Patients (by probability of transplant and OPO size)
- b. Monthly Mortality Rates, Status 2B Liver Patients (by probability of death and OPO size)
- 5-7** a. Monthly Liver Transplantation Rates, Status 3 Patients (by probability of transplant and OPO size)
- b. Monthly Mortality Rates, Status 3 Liver Patients (by probability of death and OPO size)

**BOXES**

- 2-1** Definitions
- 4-1** Excerpt from the 1998 Gallup Poll on Organ Donation
- 6-1** National Marrow Donor Program
- A-1** Organizations and Individuals Appearing Before the Committee
- A-2** Expert Liaisons